海外の治験の状況「前立腺癌」での検索結果
161件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- An exploratory study to assess the efficacy using imaging of oral enzalutamide in patients with therapy-resistant prostate cancer who have not been treated with androgen deprivation.
- Patients with Metastatic Prostate Cancer who have never been treated with Androgen Deprivation Therapy MedDRA version: 18.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- Austria, Belgium, Germany, Netherlands, Spain, Switzerland
- 2015-04-13
Authorised
- An exploratory study to assess the efficacy using imaging of oral Enzalutamide in patients with therapy-resistant prostate cancer who have not been treated with anti-androgens.
- Chemo-Naïve patients with Progressive Prostate Cancer who have failed Androgen Deprivation Therapy (CRPC patients) MedDRA version: 18.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- Austria, Belgium, Germany, Netherlands, Spain, Switzerland
- 2015-04-13
Recruiting
- Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer
- Locally Advanced and Metastatic Prostate Cancer
- Austria
- 2016-11-20
Not Recruiting
- A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy
- Cancer Cataract Low Bone Mineral Density Osteopenia Osteoporosis Prostate Cancer
- Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Colombia, Croatia, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hong Kong, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Malta, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom, United States of America
- 2012-08-23
Not Recruiting
- A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
- Metastatic Castrate Resistant Prostate Cancer
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Estonia, France, Germany, Greece, India, Ireland, Italy, Latvia, Lebanon, Lithuania, Mexico, Netherlands, New Zealand, Norway, Panama, Peru, Poland, Republic of Korea, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States of America
- 2012-07-16
Not Recruiting
- A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 (Zibotentan) 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Romania, Russian Federation, Serbia, South Africa, Spain, Sweden, Switzerland, Taiwan, Province of China, Turkey, United Kingdom, United States
- 2012-04-30
Authorised
- A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients
- Hormone-refractory prostate cancer MedDRA version: 9.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer
- Austria, Belgium, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Portugal, Spain, Sweden, United Kingdom
- 2007-11-20
Not Recruiting
- A randomised phase III multi-centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer
- Localised prostate cancer br>Cancer br>Prostate
- Ireland, New Zealand, Switzerland, United Kingdom
- 2005-10-12
Not recruiting
- Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
- Prostate Cancer
- Austria, Belgium, Brazil, Canada, Germany, Netherlands, Norway, United Kingdom, United States
- 2010-06-04
Not Recruiting
- A Phase III Study to Compare SonoVue Guided Prostate Biopsy With Systematic Biopsy in the Detection of Prostate Malignant Lesions in Patients With Suspected Prostate Cancer
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Austria, Belgium, France, Germany, Italy, Netherlands, United Kingdom
- 2012-10-09
